Ablynx is a biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments. It offers a portfolio of Nanobody-based therapeutic programs in several major disease areas, including inflammation, haematology, immuno-oncology and oncology.

Employee Rating

3.2More
TypeSubsidiary
Parent CompanySanofi
HQGent, BE
Founded2001
Websiteablynx.com
Cybersecurity ratingBMore
Ablynx was founded in 2001 and is headquartered in Gent, BE

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Ablynx

Bernard Delaey

Bernard Delaey

Senior Director, Regulatory Affairs
Carmen Fleurinck

Carmen Fleurinck

Senior Medical Director
Malgorzata Ciesiolka

Malgorzata Ciesiolka

Director, Business Development
Anne Brochot

Anne Brochot

Director, Pharmacometrics
Show more

Ablynx Office Locations

Ablynx has an office in Gent
Gent, BE (HQ)
Technologiepark-Zwijnaarde 21
Gent, BE
Technologiepark-Zwijnaarde 18
Show all (2)

Ablynx Financials and Metrics

Summary Metrics

Founding Date

2001

Total Funding

$498.8 m

Investors

In total, Ablynx had raised $498.8 m. Ablynx is a subsidiary of Sanofi

Ablynx Revenue

Ablynx's revenue was reported to be €85.19 m in FY, 2016 which is a 9.9% increase from the previous period.
EURFY, 2015FY, 2016

Revenue

77.5m85.2m

Revenue growth, %

10%

General and administrative expense

11.4m13.5m

R&D expense

83.1m100.3m
Annual
EURFY, 2015FY, 2016

Cash

3.6m53.4m

Accounts Receivable

9.3m4.8m

Current Assets

246.1m242.2m

PP&E

2.6m3.7m
Quarterly
EURQ2, 2015Q2, 2016

Cash

53.4m26.4m

Accounts Receivable

4.8m4.1m

Current Assets

242.2m210.5m

PP&E

3.7m3.9m
Annual
EURFY, 2015FY, 2016

Net Income

(54.5m)(1.1m)

Depreciation and Amortization

1.1m1.8m

Accounts Payable

(45.2m)(43.2m)

Cash From Operating Activities

(69.0m)(66.6m)
Quarterly
EURQ2, 2016Q2, 2017

Net Income

22.8m(25.3m)

Depreciation and Amortization

885.0k1.5m

Accounts Payable

(21.4m)(7.9m)

Cash From Operating Activities

(17.2m)(29.3m)
EURQ2, 2015

Financial Leverage

2.6 x
Show all financial metrics

Ablynx Operating Metrics

Q2, 2017

Clinical Programs

45

Patents (US)

50

Patents (Foreign)

180

Patents and Patent Applications

400
Show all operating metrics

Ablynx Cybersecurity Score

Cybersecurity ratingPremium dataset

B

84/100

SecurityScorecard logo

Ablynx Online and Social Media Presence

Embed Graph

Ablynx News and Updates

In- Depth Study in Blood-Brain Barrier Technologies Market Research 2018-2023, Key players - Allon Therapeutics, Inc., AngioChem Inc., Genzyme, CeNeRx BioPharma, Inc, Bioasis Technologies Inc., Ablynx NV, Capsulution Pharma AG and others

Global Blood-Brain Barrier Technologies market Revenue, Opportunity, Segment and Key Trends 2018-2023 Posted via Industry Today. Follow us on Twitter @IndustryToday

Nanobiotechnology Market 2018: Global Analysis by Key Players – Ablynx, CELGENE, Merck KGaA, Thermo Fisher Scientific

Wiseguyreports.Com Publish New Market Research Report On -“Nanobiotechnology Market - Global Industry Analysis, Size, Share, Trends, Growth and Forecast 2018 - 2022” Posted via Industry Today. Follow us on Twitter @IndustryToday

VC-backed Albynx debuts U.S. IPO

Ablynx, a Belgian biopharmaceutical company, has raised $200 million for its U.S. IPO after pricing its 11.4 million shares at $17.50 per share. The stock began trading October 25, 2017 on the NASDAQ under the ticker symbol “ABLX.” BofA Merrill Lynch, J.P. Morgan and Jefferies are the lead underwrit…

VC-backed Ablynx files for IPO

Ablynx, a Belgian biopharmaceutical company, has filed for an IPO. The number of shares that will be sold as well as the stock's pricing terms have yet to be set. Ablynx, which currently trades on the Euronext Brussels, is planning on listing its U.S. stock on the NASDAQ under the ticker symbol ABLX…

Ablynx Frequently Asked Questions

  • When was Ablynx founded?

    Ablynx was founded in 2001.

  • Who are Ablynx key executives?

    Ablynx's key executives are Bernard Delaey, Carmen Fleurinck and Malgorzata Ciesiolka.

  • How many employees does Ablynx have?

    Ablynx has 386 employees.

  • What is Ablynx revenue?

    Latest Ablynx annual revenue is €85.2 m.

  • What is Ablynx revenue per employee?

    Latest Ablynx revenue per employee is €220.7 k.

  • Who are Ablynx competitors?

    Competitors of Ablynx include ImmunoGen, CytomX Therapeutics and Innate Pharma.

  • Where is Ablynx headquarters?

    Ablynx headquarters is located at Technologiepark-Zwijnaarde 21, Gent.

  • Where are Ablynx offices?

    Ablynx has an office in Gent.

  • How many offices does Ablynx have?

    Ablynx has 2 offices.